2 stocks that could be slammed by Donald Trump

Donald Trump’s policies are looking like very bad news for these two UK companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Donald Trump has undoubtedly been a net positive for equities in the US. The new president’s talk of lower taxes, lower regulation and an economic stimulus programme breathed new life into the shares of banks, energy producers and builders alike. But on this side of the Atlantic I have my fears that Trump’s bombastic attacks on certain industries leaves several UK stocks in danger of being hugely negatively affected by his potential policies.

First up is speciality drug producer Shire (LSE: SHP). What worries me about Trump and Shire is that the he’s been quoted in the press as saying things such as “the pricing has been astronomical” and “you folks [drug companies] have done a very great job over the years but we have to get the prices down.

And Trump could definitely do something about bringing down drug prices either through direct legislation or giving government-run medical programmes the ability to negotiate their prices with drug makers. This is a common sense move that has somehow escaped Congress’s attention thus far.

This is a problem for all drug makers but is an extra worry for Shire as the company’s business model is based on developing drugs for rare diseases and then charging very, very high prices for the treatment.

Aside from concerns that its products may fetch lower prices, I’m also worried because Shire has taken on a whopping $23bn in net debt to fund a series of huge acquisitions that have made it a world leader in rare disease treatments. If the company’s ambitious sales and profit targets are met this won’t be a major problem, but should Trump take an axe to pharmaceutical prices, it certainly would be.

Rough seas ahead for global trade?

Also at risk of becoming collateral damage to Trump’s policies is ship broker Clarkson (LSE: CKN). It has already seen profits drop in the past year as a slowdown in demand for oil & gas-related ships and an oversupply of cargo vessels have led to low prices for bulk shipping.

The threat from Trump to Clarkson is if the new president embarks on his much-talked-about plan to impose tariffs on trading partners such as Mexico or, more worryingly, China. Were Trump to slap import taxes on goods from China, the Chinese would undoubtedly retaliate, threatening to send the volume of trade between these important partners plummeting.

This would be a problem for Clarkson because its broking services account for more than 85% of underlying pre-tax profits and would be negatively impacted should volumes and the price of cargo shipping fall.

The upside is that as a broker, Clarkson doesn’t own any ships and is paid a commission per deal arranged, so is somewhat protected from any downturn. Indeed, the company has weathered problems in the offshore oil & gas industry with aplomb and remains solidly profitable and has a cash-heavy balance sheet.

But with shares of the company trading hands at a lofty 25 times forward earnings would-be investors would do well to image the potential threat from Trump’s policies before buying shares.

Are you looking for Trump-resistant shares?

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

How high can the Lloyds share price go in 2026?

The Lloyds Bank share price has made some stellar gains in 2025, and some analysts are already forecasting further rises…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

£10,000 invested in Rolls-Royce shares at the start of 2025 is now worth…

Rolls-Royce shares have been on fire in 2025. Here is how much a ten grand stake could have turned into…

Read more »

Investing Articles

Up 25% in 2025! Are BT shares still a generational bargain with a 4.5% yield and P/E below 10?

BT shares have had another terrific year but still look good value and there's a handsome yield on offer too.…

Read more »

Investing Articles

Will the UK stock market crash in 2026?

James Beard considers the prospects for the UK stock market in 2026. In doing so, he also mentions the ‘C-word’…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Prediction: next Christmas, £5,000 invested in Tesco shares could be worth…

Tesco shares have enjoyed a solid year so far. Muhammad Cheema takes a look at whether it can continue to…

Read more »

Investing Articles

Will the Lloyds share price be the FTSE 100’s dark horse in 2026, or its black sheep?

The Lloyds Banking Group share price has outperformed the FTSE 100 in 2025. With this in mind, our writer takes…

Read more »

piggy bank, searching with binoculars
Investing Articles

£5,000 invested in ITM Power shares at the start of 2025 is now worth…

ITM Power shares have been a fantastic investment in 2025, with revenues skyrocketing over 600% since! But can the stock…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

£5,000 invested in Tesla shares at the start of 2025 is now worth…

Tesla shares have been exceptionally volatile in 2025, but have still managed to beat the market. But is it too…

Read more »